Effects Of Resovastain On The Prevention Of Experimental Diabetic Cardiomyopathy In Rats

Objective To investigate the effects of Resovastain on cardiac function of diabetic cardiomyopathy (DCM) in Wistar rats. Methods 50 8-week-old Wistar rats were divided into the following groups randomly: normal control group(n=8), DCM group(n=21)and DCM plus Resovastain group(Resovastain treatment group,n=21). The rats were fed normal diets in normal control group or high-glucose and high-calorie diets in DCM and DCM plus Resovastain group. Four weeks later, the DCM animal model was established by I. P. injection of Streptozotocin (STZ). After that, those which reached the standard were used for next procedure, while the Resovastain treatment group was filled stomach with Resovastatin(20mg/kg/d). After 20 weeks, the role of Resovastain which played in the process of DCM was observed through echocardiography (including LVIDs, LVIDd, EF, FS, valvular regurgitation, Max E wave speed, Max A wave speed, ratio of E/A, EDT', IVRT'and APV) and the detection of biochemical indices (including the serum glucose, fasting insulin, triglyceride and cholesterol). Results①At end, compared with normal control group, the body weight of other two groups declined significantly(P<0.01)and the fasting insulin level also declined (P<0.05). The level of fasting blood glucose, triglyceride increased (P<0.01). The level of cholesterol of DCM group increased (P<0.01), but there was no remarkable difference in terms of cholesterol of the Resovastain treatment group (P>0.05).②The DCM group and Resovastain treatment group had a uncommon increase on value of LVIDd and LVIDs (P< 0.01), and also had a evident increase on the incidence of valvular regurgitation (P<0.05). E/A ratio and EF declined (P<0.01). Compared with DCM group, the value of LVIDs and LVIDd were ameliorated in the Resovastain treatment group (P<0.05), while the incidence of valvular regurgitation decreased (P<0.05), E/A ratio declined, EF increased (P<0.05). Conclusions Resovastatin can improve the cardiac function and myocardial remodeling in diabetic cardiomyopathy rats to a certain extent.